Coya Therapeutics
COYA

$6.23

2.81%

Market Cap: $94.8M

About: Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.

Employees: 6

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,710 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

0% more funds holding

Funds holding: 19 [Q1] → 19 (+0) [Q2]

0% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 4

1.49% less ownership

Funds ownership: 22.97% [Q1] → 21.47% (-1.49%) [Q2]

40% less capital invested

Capital invested by funds: $33.1M [Q1] → $19.8M (-$13.3M) [Q2]

43% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 7

100% less funds holding in top 10

Funds holding in top 10: 1 [Q1] → 0 (-1) [Q2]

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$18

189%

upside

Avg. target

$18

189%

upside

High target

$18

189%

upside

1 analyst rating

1 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co.

Raghuram Selvaraju

44% 1-year accuracy

111 / 252 met price target

189%upside

$18

Buy

Initiated

16 Sept 2024

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about COYA published over the past 30 days

Coya Therapeutics Announces Subcutaneously Administered COYA 302 Elicits Direct Anti-Inflammatory Effect in Brain in a Preclinical Inflammatory Mouse Model of Parkinson's Disease

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces the direct CNS anti-inflammatory effect of subcutaneously administered COYA 302 in a preclinical inflammatory associated mouse model of Parkinson's Disease (PD). Coya's Chief Business Officer and incoming Chief Executive Officer Arun Swaminathan, Ph.D. stated: “We believe that the.

Coya Therapeutics Announces Subcutaneously Administered COYA 302 Elicits Direct Anti-Inflammatory Effect in Brain in a Preclinical Inflammatory Mouse Model of Parkinson's Disease

Coya Therapeutics to Present at Upcoming Healthcare Conferences

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that CEO Howard Berman, Ph.D. will present at two upcoming healthcare conferences. On September 26, 2024, Dr. Berman will participate in a panel discussion at Munsch Hardt's 3rd Annual Texas Health Care Transactions Conference being held at the Houstonian Hotel in Houston, Texas. T.

Coya Therapeutics to Present at Upcoming Healthcare Conferences

Coya Therapeutics Promotes Arun Swaminathan Ph.D. to Chief Executive Officer Effective November 1st, 2024

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, today announced that Arun Swaminathan Ph.D. has been promoted to the role of Chief Executive Officer effective November 1, 2024. He will succeed Dr. Howard Berman who will continue to serve in the capacity of Executive Chair. As we look forward to and prepare for the release of Alzheimer's d.

Coya Therapeutics Promotes Arun Swaminathan Ph.D. to Chief Executive Officer Effective November 1st, 2024

Coya Therapeutics Provides a Corporate Update and Reports Unaudited Second Quarter 2024 Financial Results

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a corporate update and announces its financial results for the quarter ended June 30, 2024. Recent Corporate Highlights Presented updated biomarker data in late April 2024 at the 2nd Annual Johnson Center Symposium that showed 4-HNE levels were predictive of survival in ALS (Amyotro.

Coya Therapeutics Provides a Corporate Update and Reports Unaudited Second Quarter 2024 Financial Results

Coya Therapeutics Announces that Results from a Double-Blind Placebo-Controlled Study in Alzheimer's Disease will be presented on October 29, 2024 at the Clinical Trials on Alzheimer's Disease Conference (CTAD24) in Madrid

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function announces that data from the IIT, a double-blind, placebo-controlled, phase 2 clinical trial of interleukin-2 (IL-2) in patients with mild to moderate Alzheimer's Disease, conducted at Houston Methodist Research Institute and supported by the Gates Foundation and the Alzheimer's Association w.

Coya Therapeutics Announces that Results from a Double-Blind Placebo-Controlled Study in Alzheimer's Disease will be presented on October 29, 2024 at the Clinical Trials on Alzheimer's Disease Conference (CTAD24) in Madrid

Coya Therapeutics Expands Pipeline and Intellectual Property Portfolio with Filing of New U.S. Patents for COYA 301 in Combination with Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces the filing of intellectual property protection for the combination of COYA 301, or recombinant human low dose interleukin-2 (LD IL-2), and Glucagon-Like Peptide-1 receptor agonists (GLP-1 RAs). Dr. Arun Swaminathan, Coya's Chief Business Officer, stated, “There has been an upswing.

Coya Therapeutics Expands Pipeline and Intellectual Property Portfolio with Filing of New U.S. Patents for COYA 301 in Combination with Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists

Coya Therapeutics Expands Sponsored Research Collaboration with Houston Methodist Research Institute Along with Funding from the Johnson Center for Cellular Therapeutics to Advance Regulatory T Cell Exosome Platform into the Clinic

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces the expansion of its research collaboration with the Houston Methodist Research Institute (“HMRI”) through a sponsored research agreement (SRA) covering multiple initiatives. The development and production of exosomes from patients' regulatory T cells will be funded by the Johnson.

Coya Therapeutics Expands Sponsored Research Collaboration with Houston Methodist Research Institute Along with Funding from the Johnson Center for Cellular Therapeutics to Advance Regulatory T Cell Exosome Platform into the Clinic

Coya Therapeutics Announces Publication of ALS Study in Peer-Reviewed Journal Frontiers in Neurology

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologic intended to enhance regulatory T cell (Treg) function, announces the publication of a peer-reviewed manuscript titled, “A Phase 1 Proof-of-Concept Study Evaluating Safety, Tolerability, and Biological Marker Responses with Combination Therapy of CTLA4-Ig and Interleukin-2 in Amyotrophic Lateral Sclerosis,” in the medical journal Frontiers in Neur.

Coya Therapeutics Announces Publication of ALS Study in Peer-Reviewed Journal Frontiers in Neurology

Coya Therapeutics: Potential Milestone For The Treatment Of Alzheimer's This Summer

Coya Therapeutics is set to initiate a Phase 2 trial in ALS and release the topline results of a Phase 2 trial in Alzheimer's disease in the summer. The company's anti-inflammatory approach has received strong external validation. Recently, small open-label clinical trials in ALS and Alzheimer's have shown improvement or disease stabilization.

Coya Therapeutics: Potential Milestone For The Treatment Of Alzheimer's This Summer

Coya Therapeutics Announces Acceptance of Peer-Reviewed Manuscript in the Medical Journal: Frontiers in Neurology

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologic intended to enhance regulatory T cell (Treg) function, announces the acceptance of a peer-reviewed manuscript titled, “A Phase 1 Proof-of-Concept Study Evaluating Safety, Tolerability, and Biological Marker Responses with Combination Therapy of CTLA4-Ig and Interleukin-2 in Amyotrophic Lateral Sclerosis,” in the medical journal Frontiers in Neuro.

Coya Therapeutics Announces Acceptance of Peer-Reviewed Manuscript in the Medical Journal: Frontiers in Neurology

See News Rankings